Table 2.

Univariate and multivariate prognostic analysis of OS in patients

	Univariate		Multivariate
	Hazard ratio (CI)	p value	Hazard ratio (CI)	p value
Sex	1.003(0.672–1.497)	0.987
Age (≥ 60 vs < 60)	1.656(1.108–2.474)	< 0.01*	1.411(0.969–2.055)	0.072
ECOG (> 1 vs 0–1)	0.989(0.707–1.384)	0.951
Extranodal sites (> 1 vs 0–1)	1.452(0.973–2.167)	0.067	1.030(0.709–1.497)	0.87
Bulky(positive vs negative)	1.390(0.896–2.156)	0.141
Cell of origin (non-GCB vs GCB)	1.049(0.779–1.410)	0.75
First-line chemotherapy regimens	1.015 (0.850–1.211)	0.87
Assessment of efficacy	1.352(1.127–1.623)	< 0.001*	1.221(1.046–1.426)	0.01
BCL-2(positive vs negative)	1.796(1.074–3.004)	0.02*	1.118(0.757–1.846)	0.461
BCL-6(positive vs negative)	1.395(0.815–2.385)	0.22
C-MYC(positive vs negative)	2.142(1.243–3.690)	< 0.001*	1.066(0.661–1.720)	0.793
CD10(positive vs negative)	1.253(0.807–1.944)	0.314
CD5(positive vs negative)	1.804(1.212–2.683)	0.003*	1.112(0.763–1.623)	0.578
KI-67(> 70% vs ≤ 70%)	3.046(1.696–5.470)	< 0.001*	2.725(1.628–4.561)	< 0.001*
HBsAg status (positive vs negative)	0.877(0.497–1.546)	0.65
LDH (abnormal vs normal)	1.589(1.064–2.372)	0.02*	1.451(0.998–2.110)	0.050*
PLT(> 100 vs ≤ 100)	0.697(0.361–1.345)	0.28
HB(> 120 vs ≤ 120)	0.649(0.428–0.985)	0.04*	0.751(0.470–1.199)	0.23
FER(> 130 vs ≤ 130)	5.571(3.416–9.085)	< 0.001*	2.424(1.482–3.964)	< 0.001*
β2 microglobulin(> 3.05 vs ≤ 3.05)	7.097(4.350–11.580)	< 0.001*	3.301(1.987–5.482)	< 0.001*
Alb(> 40vs ≤ 40)	0.672(0.450–1.01)	0.053*	0.8668( 0.574–1.307)	0.493

*p < 0.05